Johnson & Johnson’s Varipulse Device Continues to Drive Growth
Johnson & Johnson’s Varipulse catheter remains a key growth driver for the company, according to RBC Capital Markets. In a note emailed on Wednesday, RBC emphasized that there has been no change in the device’s intended use case.
- The company announced last week that it would resume the limited market release of Varipulse in the US.
- This decision follows an investigation that confirmed the device operates as intended.
- Global updates to the device’s instructions for use will include enhanced guidance for improved clarity.
Device Usage and Market Potential
RBC analysts, including Shagun Singh, noted that the Varipulse catheter is now more likely to be used in treating paroxysmal patients rather than in persistent patients off-label.
- They highlighted the significant potential for pulsed field ablation in the treatment of atrial fibrillation.
- The atrial fibrillation market remains under-penetrated, with only about 5% of the market currently reached.
Stock Performance and Outlook
RBC has maintained an outperform rating and set a price target of $181 for Johnson & Johnson stock.
- In recent trading, Johnson & Johnson shares were up 1.4%, reflecting a $2.19 increase, bringing the price to $157.18.